Saram ConsultingGxP & AI Consulting for Life Sciences. Custom AI integrations, Part 11 compliance validation, and equity-based engineering partnerships for biotech.Explore Services at saram.io →
← Back to Home

CeleCor Therapeutics

Private
#Cardiology#Cardiovascular#Acute Coronary Syndrome

Clinical-stage biotechnology company developing pre-hospital therapies for heart attacks, led by zalunfiban (RUC-4), an investigational subcutaneous GPIIb/IIIa platelet inhibitor designed for first-medical-contact treatment of STEMI.

Company Info

Sector:Cardiovascular
Headquarters:Del Mar, California, USA
Founded:2017
Website:www.celecor.com/

Clinical Development Pipeline

zalunfiban (RUC-4)

Target: GPIIb/IIIa platelet receptor
ST-elevation myocardial infarction (STEMI), pre-hospital
Preclinical
Phase 1
Phase 2
Phase 3
Approved

zalunfiban (RUC-4)

Target: GPIIb/IIIa platelet receptor
Acute coronary syndrome
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Recent News

Leadership Team

Barry S. Coller

Founder

Careers & Job Openings

See all open roles

All departments
Various
Apply Now →